Extended Data Fig. 8: Most frequent serious adverse events by baseline SGLT2i use; by system organ class (a) and by preferred term (b). | Nature Medicine

Extended Data Fig. 8: Most frequent serious adverse events by baseline SGLT2i use; by system organ class (a) and by preferred term (b).

From: Effects of semaglutide with and without concomitant SGLT2 inhibitor use in participants with type 2 diabetes and chronic kidney disease in the FLOW trial

Extended Data Fig. 8

Percentages are sorted in descending order by the frequency in the semaglutide 1.0 mg group. Most frequent was defined as the 10 most frequent terms by absolute count, where absolute count was >1 in the total population (up to 15 in case of a tie). N, number of participants in the semaglutide and placebo arms. COVID-19, coronavirus disease 2019; SGLT2i, sodium-glucose co-transporter-2 inhibitors. Note that the percentage range (abscissa) varies.

Back to article page